NASDAQ:DAWN • US23954D1090
Past quarterly earnings results for DAY ONE BIOPHARMACEUTICALS I (DAWN), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Actual vs estimated values, surprises, q2q growth and acceleration numbers for recent quarters.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | -0.21 | -0.15 | -35.56% | 67.19% | 53.718M | 49.538M | 8.44% | 83.97% |
| Q3 2025 | -0.19 | -0.30 | 36.38% | 48.65% | 39.795M | 38.964M | 2.13% | 98.28% |
| Q2 2025 | -0.29 | -0.36 | 20.33% | -480.00% | 33.908M | 36.007M | -5.83% | 313.92% |
| Q1 2025 | -0.35 | -0.45 | 22.45% | 51.39% | 30.761M | 30.842M | -0.26% | - |
| Q4 2024 | -0.64 | -0.37 | -73.33% | - | 29.2M | 28.348M | 3.01% | - |
| Q3 2024 | -0.37 | -0.42 | 11.53% | 31.48% | 20.07M | 24.016M | -16.43% | - |
| Q2 2024 | -0.05 | -0.77 | 93.47% | 91.80% | 8.192M | 1.042M | 686.18% | - |
| Q1 2024 | -0.72 | -0.68 | -6.41% | -22.03% | - | - | ||
| Q4 2023 | -0.64 | -0.59 | -7.56% | -14.29% | - | - | ||
| Q3 2023 | -0.54 | -0.61 | 12.11% | -1.89% | - | - | ||
| Q2 2023 | -0.61 | -0.62 | 1.98% | -1.67% | - | - | ||
| Q1 2023 | -0.59 | -0.60 | 2.33% | -22.92% | - | - | ||
| Q4 2022 | -0.56 | -0.58 | 3.12% | -55.56% | - | - | ||
| Q3 2022 | -0.53 | -0.54 | 2.70% | -60.61% | - | - | ||
| Q2 2022 | -0.60 | -0.50 | -20.66% | 88.10% | - | - | ||
| Q1 2022 | -0.48 | -0.39 | -22.23% | - | - | - | ||
| Q4 2021 | -0.36 | -0.36 | 1.28% | - | - | - | ||
| Q3 2021 | -0.33 | -0.29 | -15.44% | - | - | - | ||
| Q2 2021 | -5.04 | -0.32 | -1,468.63% | - | - | - | ||
| Q1 2021 | - | - | - | - | ||||
| Q4 2020 | - | - | - | - | ||||
| Q3 2020 | - | - | - | - | ||||
| Q2 2020 | - | - | - | - | ||||
| Q1 2020 | - | - | - | - |
Notes
DAY ONE BIOPHARMACEUTICALS I (DAWN) last reported earnings on 2/24/2026.
DAY ONE BIOPHARMACEUTICALS I (DAWN) missed EPS estimates and beat revenue estimates in the most recent quarter.
In the last 4 quarters, DAY ONE BIOPHARMACEUTICALS I (DAWN) has beaten EPS estimates in 3 out of 4 releases.